Niigata, Japan – A group of Scientists at the Department of Neurosurgery, Brain Research Institute, Niigata University succeeded in the diagnosis of leptomeningeal disease in diffuse midline gliomas by detecting H3K27M-mutant droplets from circulating tumor DNA of cerebrospinal fluid taken from these patients. In two patients, leptomeningeal disease was diagnosed...
research News
Niigata, Japan –Dialysis patients often develop dialysis-related amyloidosis and exhibit bone and joint disorders that impair their activity of daily living. Blood purification devices consisting of hexadecyl-immobilized cellulose beads aimed at removing the precursor protein, β2– microglobulin (β2-m), are used in the treatment of dialysis-related amyloidosis. Dr. Yamamoto et al....
MISSISSAUGA – YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that results from a randomized trial of nimotuzumab (aka BIOMAb/TheraCIM/h-R3) in patients with inoperable, locoregionally advanced...
Denver, CO – Researchers have shown that the drug benralizumab is as effective and safe as mepolizumab for inducing remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) according to a study published today in The New England Journal of Medicine. The results of the non-inferiority study were presented at...
SANTA ANA, Calif. — NKGen Biotech Inc., a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced that it has received a No Objection Letter (“NOL”) from Health Canada for its Clinical Trial Application (“CTA”) for a Phase...
SANTA ANA, Calif. — NKGen Biotech, Inc., a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced the dosing of the first patient in its Phase 1/2a trial evaluating SNK01, a cryopreserved autologous, non-genetically modified NK cell therapy...
Curing cancer has been the dream of countless doctors and researchers over the decades. Yet some types of cancer, whether because they affect relatively few people or lack influential advocates, receive less attention and funding than others. A recent gift to Harvard Medical School (HMS) is boosting efforts to understand...
BOSTON, Mass. – NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, today announces positive data from its Phase Ib/IIa study in Parkinson’s disease patients, evaluating the effects of its oral, brain-penetrant NLRP3 inflammasome inhibitor NT-0796, on inflammatory and disease-specific biomarkers in the blood...
Deep vein thrombosis (DVT) after laparoscopic hepatectomy may be high, and no effective risk assessment methods exist. The authors of a study published in the Journal of Hepatocellular Carcinoma estimated incidence of DVT after surgery and created a DVT risk nomogram. The western hemisphere has well-established guidelines for thromboprophylaxis, but its application...
WASHINGTON, DC — The future of rare disease advancements will take center stage at the National Organization for Rare Disorders (NORD®) Rare Disease and Orphan Products Breakthrough Summit®, Oct. 19-21 in Washington. NORD is proud to announce the top researchers selected for the Lightning Rounds Poster Presentations session. Chosen from a competitive...